Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro

Subvisible proteinaceous particles which are present in all therapeutic protein formulations are in the focus of intense discussions between health authorities, academics and biopharmaceutical companies in the context of concerns that such particles could promote unwanted immunogenicity via anti-drug antibody formation. In order to provide further understanding of the subject, this study closely examines the specific biological effects proteinaceous particles may exert on dendritic cells (DCs) as the most efficient antigen-presenting cell population crucial for the initiation of the adaptive immune response. Two different model IgG antibodies were subjected to three different types of exaggerated physical stress to generate subvisible particles in far greater concentrations than the ones typical for the currently marketed biotherapeutical antibodies. The aggregated samples were used in in vitro biological assays in order to interrogate the early DC-driven events that initiate CD4 T-cell dependent humoral adaptive immune responses – peptide presentation capacity and co-stimulatory activity of DCs. Most importantly, antigen presentation was addressed with a unique approach called MHC-associated Peptide Proteomics (MAPPs), which allows for identifying the sequences of HLA-DR associated peptides directly from human dendritic cells. The experiments demonstrated that highly aggregated solutions of two model mAbs generated under controlled conditions can induce activation of human monocyte-derived DCs as indicated by upregulation of typical maturation markers including co-stimulatory molecules necessary for CD4 T-cell activation. Additional data suggest that highly aggregated proteins could induce in vitro T-cell responses. Intriguingly, strong aggregation-mediated changes in the pattern and quantity of antigen-derived HLA-DR associated peptides presented on DCs were observed, indicating a change in protein processing and presentation. Increasing the amounts of subvisible proteinaceous particles correlated very well with the pronounced increase in the peptide number and clusters presented in the context of class II HLA-DR molecules, suggesting a major involvement of a mass-action mechanism of altering the presentation.

[1]  Theodore W Randolph,et al.  Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. , 2011, Journal of pharmaceutical sciences.

[2]  J. Paul Robinson,et al.  Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. , 2005, Vaccine.

[3]  Huub Schellekens,et al.  Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice , 2010, Pharmaceutical Research.

[4]  Mark M. Davis,et al.  T-cell-antigen recognition and the immunological synapse , 2003, Nature Reviews Immunology.

[5]  Yuzhang Wu,et al.  Terminal complement complex C5b‐9‐treated human monocyte‐derived dendritic cells undergo maturation and induce Th1 polarization , 2007, European journal of immunology.

[6]  P. Matzinger,et al.  Danger signals: SOS to the immune system. , 2001, Current opinion in immunology.

[7]  Francisco A. Chaves,et al.  The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes , 2005, Immunological reviews.

[8]  S. Singh,et al.  An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.

[9]  P. Lackner,et al.  Nitration of the Pollen Allergen Bet v 1.0101 Enhances the Presentation of Bet v 1-Derived Peptides by HLA-DR on Human Dendritic Cells , 2012, PloS one.

[10]  F. Chiti,et al.  Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. , 2008, Current opinion in structural biology.

[11]  Joaquín Dopazo,et al.  An Evolutionary Trade-Off between Protein Turnover Rate and Protein Aggregation Favors a Higher Aggregation Propensity in Fast Degrading Proteins , 2011, PLoS Comput. Biol..

[12]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[13]  G. Obermoser,et al.  Cross-Linking of CD32 Induces Maturation of Human Monocyte-Derived Dendritic Cells Via NF-κB Signaling Pathway1 , 2003, The Journal of Immunology.

[14]  E. Sercarz,et al.  MHC-guided processing: binding of large antigen fragments , 2003, Nature Reviews Immunology.

[15]  J. Ravetch,et al.  Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. , 2005, The Journal of clinical investigation.

[16]  S. Thiel,et al.  Complement protein C1q induces maturation of human dendritic cells. , 2007, Molecular immunology.

[17]  R. Steinman,et al.  Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Steven Kozlowski,et al.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.

[19]  J. Köhl,et al.  Impaired dendritic cell differentiation and maturation in the absence of C3. , 2007, Molecular immunology.

[20]  K. Braeckmans,et al.  Detection and Characterization of Subvisible Aggregates of Monoclonal IgG in Serum , 2012, Pharmaceutical Research.

[21]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[22]  R. Steinman,et al.  Dendritic cells: translating innate to adaptive immunity. , 2006, Current topics in microbiology and immunology.

[23]  Hidde L. Ploegh,et al.  The known unknowns of antigen processing and presentation , 2008, Nature Reviews Immunology.

[24]  W. Jiskoot,et al.  In Vivo Fluorescence Imaging of IgG1 Aggregates After Subcutaneous and Intravenous Injection in Mice , 2013, Pharmaceutical Research.

[25]  C. Dobson,et al.  Bridging the gap: From protein misfolding to protein misfolding diseases , 2009, FEBS letters.

[26]  M. Joubert,et al.  Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses , 2012, The Journal of Biological Chemistry.

[27]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[28]  A. Erdei,et al.  Expression and role of Fc- and complement-receptors on human dendritic cells. , 2006, Immunology letters.

[29]  M. Lotze,et al.  The grateful dead: damage‐associated molecular pattern molecules and reduction/oxidation regulate immunity , 2007, Immunological reviews.

[30]  M. Foti,et al.  Early events in dendritic cell maturation induced by LPS. , 1999, Microbes and infection.